CLAIMS

1. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less filled in a multidose-type eye drop container, wherein the amount of the aqueous ophthalmic composition to be filled is 1 to 10 mL.

2. The aqueous ophthalmic composition according to claim 1, further comprising a silver salt.

3. The aqueous ophthalmic composition according to claim 2, wherein the silver salt comprises silver nitrate.

4. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

5. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

6. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 3% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

7. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value

of more than 30 and 120 or less filled in a multidose-type eye drop container.

8. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 5 mL of an aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less filled in a multidose-type eye drop container.

9. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less filled in a PFMD container.

10. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 5 mL of an aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less filled in a PFMD container.

11. The ophthalmic medicament product according to any one of claims 7 to 10, wherein the aqueous ophthalmic composition comprises diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

12. The ophthalmic medicament product according to any one of claims 7 to 10, wherein the aqueous composition comprises diquafosol sodium at a concentration of 1 to 5% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

13. The ophthalmic medicament product according to any one of claims 7 to 10, wherein the aqueous composition comprises diquafosol sodium at a concentration of 3% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

14. The aqueous ophthalmic composition according to any one of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of 90 or more.

15. The aqueous ophthalmic composition according to any one of claims 1 to 6, wherein the concentration of the polyvinylpyrrolidone is 0.001% (w/v) or more.

16. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the concentration of the diquafosol sodium is 3% (w/v).

17. The aqueous ophthalmic composition according to any one of claims 1 to 6, wherein the aqueous ophthalmic composition has a pH in the range of 6 to 8.

18. The aqueous ophthalmic composition according to any one of claims 1 to 6, wherein the aqueous ophthalmic composition has a pH in the range of 7 to 8.

19. The aqueous ophthalmic composition according to any one of claims 1 to 6, wherein the aqueous ophthalmic composition is a sterile aqueous ophthalmic solution.

20. The aqueous ophthalmic composition according to any one of claims 1 to 6, wherein the aqueous ophthalmic composition is preservable at room temperature.

21. The aqueous ophthalmic composition according to any one of claims 1 to 4, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 1.5 to 30 mPa·s.